Citius Pharmaceuticals, Inc. (CTXR)
US — Healthcare Sector
Automate Your Wheel Strategy on CTXR
With Tiblio's Option Bot, you can configure your own wheel strategy including CTXR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CTXR
- Rev/Share 0.0009
- Book/Share 0.3657
- PB 2.4528
- Debt/Equity 0.0154
- CurrentRatio 0.3684
- ROIC -0.4506
- MktCap 8806439.0
- FreeCF/Share -0.1541
- PFCF -0.3287
- PE -3.4891
- Debt/Assets 0.0077
- DivYield 0
- ROE -0.6052
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CTXR | D. Boral Capital | Hold | Buy | -- | $9 | Dec. 30, 2024 |
News
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
CTOR,
CTXR
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral
CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024.
Read More
About Citius Pharmaceuticals, Inc. (CTXR)
- IPO Date 2014-10-02
- Website https://www.citiuspharma.com
- Industry Biotechnology
- CEO Mr. Leonard L. Mazur
- Employees 23
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.